People | Locations | Statistics |
---|---|---|
Naji, M. |
| |
Motta, Antonella |
| |
Aletan, Dirar |
| |
Mohamed, Tarek |
| |
Ertürk, Emre |
| |
Taccardi, Nicola |
| |
Kononenko, Denys |
| |
Petrov, R. H. | Madrid |
|
Alshaaer, Mazen | Brussels |
|
Bih, L. |
| |
Casati, R. |
| |
Muller, Hermance |
| |
Kočí, Jan | Prague |
|
Šuljagić, Marija |
| |
Kalteremidou, Kalliopi-Artemi | Brussels |
|
Azam, Siraj |
| |
Ospanova, Alyiya |
| |
Blanpain, Bart |
| |
Ali, M. A. |
| |
Popa, V. |
| |
Rančić, M. |
| |
Ollier, Nadège |
| |
Azevedo, Nuno Monteiro |
| |
Landes, Michael |
| |
Rignanese, Gian-Marco |
|
Bryszewska, Maria
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (22/22 displayed)
- 2024Recent advances in multifunctional dendrimer‐based complexes for cancer treatmentcitations
- 2023Ruthenium metallodendrimer against triple-negative breast cancer in micecitations
- 2023Boron nitride embedded in chitosan hydrogel as a hydrophobic, promising metal-free, sustainable antibacterial materialcitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Modelscitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary studycitations
- 2022Heterofunctionalized polyphenolic dendrimers decorated with caffeic acid: Synthesis, characterization and antioxidant activitycitations
- 2021Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNAcitations
- 2020Copper (II) metallodendrimers combined with pro- apaoptotic siRNAs as a promising strategy against breast cancer cellscitations
- 2020Glucose-modified carbosilane dendrimers: Interaction with model membranes and human serum albumincitations
- 2019Immunoreactivity changes of human serum albumin and alpha-1-microglobulin induced by their interaction with dendrimerscitations
- 2019Dendrimers and hyperbranched structures for biomedical applicationscitations
- 2019Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drugcitations
- 2019Dendrimer for Templating the Growth of Porous Catechol-Coordinated Titanium Dioxide Frameworks: Toward Hemocompatible Nanomaterialscitations
- 2018Ruthenium dendrimers as carriers for anticancer siRNAcitations
- 2016Fourier transform infrared spectroscopy (FTIR) characterization of the interaction of anti-cancer photosensitizers with dendrimerscitations
- 2015Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological actioncitations
- 2013Dendrimers as Antiamyloidogenic Agents. Dendrimer-amyloid Aggregates Morphology and Cell Toxicitycitations
- 2013Characterization of Dendrimers and Their Interactions with Biomolecules for Medical use by Means of Electron Magnetic Resonancecitations
- 2013Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applicationscitations
Places of action
Organizations | Location | People |
---|
booksection
Dendrimers as Antiamyloidogenic Agents. Dendrimer-amyloid Aggregates Morphology and Cell Toxicity
Abstract
Dendrimers are branched polymeric structures that have been shown to have a promising antiamyloidogenic potential by interfering with the polymerization process leading to the formation of the amyloid aggregates related to conformational diseases, such as Alzheimer's and prion diseases. It has been established that there is a relationship between the morphology of the amyloid aggregates and the amyloid peptides or proteins toxicity: fibrillar structures present low or no toxicity, whereas oligomeric species and amorphous aggregates, the so called granular non‐fibrillar aggregates (GNAs), are toxic to cells. When interacting with the amyloid peptide associated to the onset and development of Alzheimer's disease, dendrimers can either accelerate the formation of fibrillar structures or inhibit it. Inhibition however may mean promoting the formation of amorphous aggregates. We summarize in the present chapter the experimental evidence showing that when used in a way that favors the formation and clumping of fibrils, dendrimers (glycodendrimers in particular) can reduce amyloid toxicity. However the same glycodendrimers used under different conditions can generate toxic GNAs, an aggregated form that could represent a general morphological signature for amyloid toxicity.